Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319817 | 0.94 | CYP3A4 (0.60) | CYP3A4GRM2RAB9ASMN1; SMN2 | |
| SCHEMBL2317458 | 0.86 | CYP3A4 (0.55) | CYP3A4GRM2RAB9ASMN1; SMN2 | |
| SCHEMBL5563880 | 0.84 | CYP3A4 (0.69) | CYP3A4GRM2 | |
| SCHEMBL5558069 | 0.83 | CYP3A4 (0.66) | CYP3A4GRM2 | |
| SCHEMBL5557011 | 0.83 | CYP3A4 (0.65) | CYP3A4GRM2RAB9ASMN1; SMN2 | |
| SCHEMBL5562094 | 0.83 | CYP3A4 (0.67) | CYP3A4GRM2 | |
| SCHEMBL2319477 | 0.82 | CYP3A4 (0.57) | CYP3A4GRM2RAB9ASMN1; SMN2 | |
| SCHEMBL2319292 | 0.82 | CYP3A4 (0.66) | CYP3A4RAB9ASMN1; SMN2 | |
| SCHEMBL2316865 | 0.82 | GRM2 (0.71) | CYP3A4GRM2 | |
| SCHEMBL5563757 | 0.81 | CYP3A4 (0.60) | CYP3A4GRM2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137167-B1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | claimed |
| EP-2137167-A1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-12-30 | — | — | EP | claimed |
| US-7511033-B2 | Dihydro-benzo[B][1,4]diazepin-2-one sulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-31 | — | — | US | claimed |
| WO-2008128889-A1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | WO | claimed |
| US-20080261957-A1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-23 | — | — | US | claimed |
| EP-2137167-B1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2137167-A1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-12-30 | — | — | EP | disclosed |
| US-7511033-B2 | Dihydro-benzo[B][1,4]diazepin-2-one sulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-31 | — | — | US | disclosed |
| WO-2008128889-A1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261957-A1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261957-A1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, CNR1 | CYP3A4 251/4885GRM2 69/4885RAB9A 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.